alexa Preventing radiation retinopathy with hyperfractionation.


Biochemistry & Physiology: Open Access

Author(s): Monroe AT, Bhandare N, Morris CG, Mendenhall WM

Abstract Share this page

Abstract PURPOSE: The purpose of this study was to determine factors associated with the development of radiation retinopathy in a large series of patients with head-and-neck cancer. In particular, we addressed whether the use of hyperfractionated radiation therapy was effective in reducing the risk of retinopathy. METHODS AND MATERIALS: One hundred eighty-six patients received a significant dose to the retina as part of curative radiotherapy. Primary sites included: nasopharynx, 46; paranasal sinus, 64; nasal cavity, 69; and palate, 7. Prescription doses varied depending on primary site and histology. Hyperfractionated (twice-daily) radiation was delivered to 42\% of the patients in this study, typically at 1.10 to 1.20 Gy per fraction. The remainder were treated once-daily. Retinal doses were determined from computerized dosimetry plans when available. For all other patients, retinal doses were retrospectively calculated using reconstructed off-axis dosimetry taken from contours through the center of the globes. Retinal dose was defined as the minimum dose received by at least 25\% of the globe. The median retinal dose was 56.85 Gy. Patients were followed for a median of 7.6 years. RESULTS: Thirty-one eyes in 30 patients developed radiation retinopathy, resulting in monocular blindness in 25, bilateral blindness in 1, and decreased visual acuity in 4. The median time to the diagnosis of retinopathy was 2.6 years (range, 11 months to 5.3 years). The actuarial incidence of developing radiation retinopathy was 20\% at both 5 and 10 years. The incidence of developing ipsilateral blindness due to retinopathy was 16\% at 5 years and 17\% at 10 years. Site-specific incidences varied considerably, with ethmoid sinus (9 of 25, 36\%), nasal cavity (13 of 69, 19\%), and maxillary sinus (6 of 35, 17\%) being the most common sites associated with radiation retinopathy. Three of 72 patients (4\%) receiving retinal doses less than 50 Gy developed retinopathy. Higher retinal doses resulted in a steady increase in the incidence of retinopathy, with 25 of the 30 cases occurring after 60 Gy or more. Of the patients receiving more than 50 Gy to the retina, hyperfractionation was associated with a significantly lower incidence of radiation retinopathy (37\% vs. 13\%; p = 0.0037). On multivariate analysis, retinal dose (p < 0.0001), fractionation schedule (p = 0.0003), age (p = 0.0365), and prolonged overall treatment time (p = 0.0213) were significant predictors of radiation retinopathy. CONCLUSION: The incidence of ipsilateral radiation retinopathy after treatment of nasal cavity/paranasal tumors is 20\% at 5 and 10 years. Retinal dose and fractionation schedule are the strongest predictors of retinopathy. Hyperfractionated radiotherapy is associated with a significant reduction in the incidence of radiation retinopathy, especially when the retina receives more than 50 Gy. This article was published in Int J Radiat Oncol Biol Phys and referenced in Biochemistry & Physiology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 9th International Conference on Structural Biology
    September 18-20, 2017 Zurich, Switzerland

  •  2nd International Conference on Biochemistry
    Sep 21-22, 2017, Macau, Hong Kong
  • 2nd International Conference on Biochemistry
    September 28-29, 2017 Dubai, UAE

  • 3rd Annual Congress on Bioscience
    October 16-17, 2017 Dubai,UAE

  • 3rd International Conference on Transcriptomics
    October 30 - November 01, 2017 Bangkok, Thailand

  • 3rd International Conference on Genetic and Protein Engineering (10 Plenary Forums - 1 Event)
    November 08-09, 2017 Las Vegas, USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version